All In Biotech

NDA 022074 · Ipsen Pharma

Somatuline Depot

Lanreotide Acetate · Subcutaneous

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Aug 30, 2007

Approved uses

4

Original approval plus efficacy supplements

Registered trials

84

39 Phase 3, 6 recruiting

FAERS reports

7,953

4,731 serious, 1,485 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 11, 2024.

SOMATULINE DEPOT is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 ) 1.1 Acromegaly SOMATULINE DEPOT is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal. 1.2 Gastroenteropancreatic Neuroendocrine Tumors SOMATULINE DEPOT is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. 1.3 Carcinoid Syndrome SOMATULINE DEPOT is indicated for the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.

Mechanism: Lanreotide, the active component of SOMATULINE DEPOT is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • SOMATULINE DEPOT · LANREOTIDE ACETATE EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AB
  • SOMATULINE DEPOT · LANREOTIDE ACETATE EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AB
  • SOMATULINE DEPOT · LANREOTIDE ACETATE EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lanreotide" as an intervention, any sponsor and status, largest first.

All 84 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,514
  • diarrhoea1,440
  • death1,278
  • fatigue983
  • nausea735
  • injection site pain601
  • abdominal pain573
  • headache507
  • malaise446
  • dizziness422
  • asthenia418
  • weight decreased409

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20062
20074
200815
20094
201078
201167
201275
201341
201431
201526
201641
20171,043
2018237
2019277
2020360
2021973
20221,265
20231,154
2024836
2025913
2026511

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Somatuline Depot (Lanreotide Acetate)

2024 spending

$57.7M

Beneficiaries

910

6,398 claims

Per beneficiary

$63,440

$21,089.27 per unit

View as table
YearSpending
2020$43,799,697
2021$45,711,867
2022$49,718,007
2023$53,027,638
2024$57,730,049

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 222 on PubMed

Sponsor: Ipsen Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.